In This Article:
-
Research and Development Expenses: $16.2 million for Q2 2024, down from $31 million in Q2 2023.
-
General and Administrative Expenses: $5.8 million for Q2 2024, compared to $6.2 million in Q2 2023.
-
Net Loss: $21.1 million for Q2 2024, compared to $35.8 million in Q2 2023.
-
Net Cash Used in Operating Activities: $50 million for the six months ended June 30, 2024, compared to $46.7 million for the same period in 2023.
-
Cash Use for the Quarter: $19 million for Q2 2024, compared to $30.8 million in Q1 2024.
-
Cash and Cash Equivalents: $61.7 million as of June 30, 2024, compared to $111.5 million as of December 31, 2023.
Release Date: August 08, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
BioAtla Inc (NASDAQ:BCAB) received a Fast Track designation from the FDA for ozuriftamab vedotin, highlighting its potential in treating refractory head and neck cancer.
-
The company reported a manageable safety profile with no new safety signals for its CAB-ROR2-ADC ozuriftamab vedotin.
-
BioAtla Inc (NASDAQ:BCAB) observed promising clinical benefits in patients with KRAS mutations, including a complete response maintained for over two years.
-
The company is on track to meet with the FDA to discuss potentially registrational trials for its CAB-ROR2 and CAB CTLA-4 assets.
-
BioAtla Inc (NASDAQ:BCAB) is in meaningful discussions regarding potential strategic partnerships, with confidence in establishing collaborations this year.
Negative Points
-
Research and development expenses decreased significantly, indicating potential challenges in sustaining the same level of innovation and development.
-
Net loss for the quarter was $21.1 million, although reduced from the previous year, it still represents a significant financial challenge.
-
Cash and cash equivalents decreased from $111.5 million at the end of 2023 to $61.7 million as of June 30, 2024, raising concerns about long-term financial sustainability.
-
The company has not yet met with the FDA regarding recent enrollment data for its UPS study, indicating potential delays in regulatory progress.
-
BioAtla Inc (NASDAQ:BCAB) is not currently enrolling new patients in certain programs, which may slow down the pace of clinical development.
Q & A Highlights
Q: Can you confirm if you have met with the FDA regarding the AXL and UPS registrational study, and what feedback have you received? Also, could you provide more details on patient compliance and safety profile? A: We have discussed mecbotamab vedotin in undifferentiated pleomorphic sarcoma with the FDA, including Project Optimus requirements and potential accelerated approval with a single-arm trial. We haven't met with the agency regarding recent patient enrollment but plan to update in the second half of the year. No new safety findings have been identified, and we focus on a more patient-compliant dosing regimen.